Aster Hospitals Bangalore launches 'Aster International Institute of Oncology'
Aims to provide comprehensive cancer care under one roof
Bengaluru: Aster Hospitals Bangalore, a unit of Aster DM Healthcare has launched an institute of oncology under the banner - Aster International Institute of Oncology (AIIO) today. This newly launched institute will be the centre of excellence in the treatment of all cancers under a single roof. The state-of-the-art institute was launched by Dr. Azad Moopen, Founder Chairman and Managing Director, Aster DM Healthcare in the presence of Prof. Dr. Somashekhar S P, Chairman of Medical Advisory Board and Global Director of Aster International Institute of Oncology, Aster DM Healthcare - India & GCC and Dr. Nitish Shetty, Regional Director, Karnataka & Maharashtra, Aster DM Healthcare.
AIIO will provide comprehensive cancer care services to all, which includes Surgical Oncology, Ortho Onco, GynecOnco, Uro-onco, Robotics, SLNB, HIPEC, PIPAC, Breast Oncoplasty, Intraoperative Radiotherpy, MicrovascularAdvanced Plastic Surgery, Lymphoedema Clinic, Medical Oncology, Haematology, Haemato-Oncology, Stem Cell and Bone Marrow, Nuclear Medicine, Nuclear Medicine Therapy center, Oncopathology, Oncogenetics, Pain and Palliative, Hospice Care, Intervention Radiology, Intervention GI, Pulmonology, Nephro, Cardiac, ICU.
Commenting on the need to establish a comprehensive cancer care institute in India, Dr. Azad Moopen, Founder Chairman and Managing Director, Aster DM Healthcare, said “Cancer is emerging as major public health problems in India. On an average, more than 1,300 Indians succumb to the dreadful disease every day. There is a need for specialised infrastructure and expertise in the treatment of cancer. Keeping this in mind, we have launched Aster International Institute of Oncology, which will be spearheaded by Prof. Dr. Somashekhar S P. It is a centre of excellence for Cancer Care and Robotic Surgery, offering the entire range of oncology-related services, backed by an experienced team of doctors, cutting-edge technologies, and the latest innovations in cancer care.”
Speaking on the launch, Prof. Dr. Somashekhar S P, Chairman of Medical Advisory Board and Global Director of Aster International Institute of Oncology, Aster DM Healthcare, India & GCC, said, “The idea is to establish AIIO as the number one cancer care institute in India, and soon to be in the top 5 globally. All centres will have robots, hi-tech dedicated machines, intra-operative radio therapy, state-of-the-art medical equipment. We are also partnering with top universities in the world for the research and development purposes. We are establishing training and fellowship programs in affiliation with Rajiv Gandhi University or any recognized university and offering DrNB Oncology programme. AIIO will be the exclusive research wing and for clinical trials.”
“Based on the cancer registry data, it is estimated that there will be about 8,00,000 new cancer cases in India every year. At any given point, there is likely to be 3 times this load, about 2,40,000 cases. There is an urgent need for utilization of advanced imaging diagnostics, which detect earlier stages of cancer and/or more indolent forms of cancer. With an aim to address this, we are launching Aster International Institute of Oncology. The launch will be in a phase manner. Firstly, we are concentrating in Bangalore, which will cover the whole of Karnataka soon, then Kerala and later spread out to all over India. All centres will be integrated together and will follow the same protocol in the treatment of cancer”, said, Dr. Nitish Shetty, Regional Director - Karnataka & Maharashtra, Aster DM Healthcare.
Concluding the event, Mr. S Ramesh Kumar, CEO - Aster CMI Hospital, Bangalore, said “We are happy to launch this new oncology institute which is on par with international standards. It will be a great benefit for patients in Bangalore and across the state. We need more institutions like ours to be able to reach out to maximum number of patients.”
About Aster DM Healthcare
Aster DM Healthcare Limited is one of the largest private healthcare service providers operating in GCC and in India. With an inherent emphasis on clinical excellence, we are one of the few entities in the world with a strong presence across primary, secondary, tertiary, and quaternary healthcare through our 27 hospitals, 118 clinics, 323 pharmacies and 66 labs & patient experience centres in seven countries, including India. We have over 24,350 plus dedicated staff including 3,110 doctors and 7,063 nurses across the geographies that we are present in, delivering a simple yet strong promise to our different stakeholders: "We'll treat you well." We reach out to all economic segments in the GCC states through our differentiated healthcare services across the "Aster", "Medcare" and "Access" brands.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
Rupee rises 10 paise to 92.41/USD; faces risks from rising global tensions
Mumbai (PTI): The rupee appreciated 10 paise to 92.41 against the US dollar in early trade on Friday, even as the USD/INR pair faces risks from rising global tensions, especially the US-Iran conflict.
Forex traders said the rupee is likely to see high volatility intra-day as the deadline for RBI's instructions to banks to curb their overnight positions to USD 100 million closes today.
At the interbank foreign exchange market, the rupee opened at 92.58 against the US dollar, then gained ground to touch 92.41 against the US dollar in initial trade, registering a gain of 10 paise over its previous close.
On Thursday, the rupee settled with a marginal gain of 3 paise at 92.51 against the US dollar.
"An estimated 80–85 per cent of these positions have already been unwound, which means the bulk of this supportive flow is now behind us. In simple terms, the cushion that held the rupee steady is beginning to thin, and this is where the story starts to shift," CR Forex Advisors MD Amit Pabari said.
Pabari further noted that looking ahead, the picture for the rupee appears to be changing. "With most of the NOP-related support now fading and global uncertainties still elevated, the scope for further strength seems limited. USDINR is likely to find a base in the 92.20–92.50 zone, with a gradual move higher towards 93.50–94.00 levels," he said.
Meanwhile, the dollar index, which gauges the greenback's strength against a basket of six currencies, was higher by 0.07 per cent at 98.69 as the safe-haven demand has come down after the ceasefire, but as the ceasefire is fragile, the US dollar is getting bids at lower levels.
Brent crude, the global oil benchmark, was trading higher by 0.51 per cent at USD 96.44 per barrel in futures trade, as the ongoing uncertainty over the Strait of Hormuz opening is keeping the oil trade well bid.
Pabari further noted that just as domestic support begins to fade, the global backdrop is turning uneasy again. "The World Bank has flagged that India's growth for FY27, expected at 6.6 per cent, faces risks from rising global tensions, especially the Iran conflict," he said.
According to Pabari, India continues to have strong buffers in the form of forex reserves and a stable banking system, but pressure points are slowly beginning to build.
On the domestic equity market front, the stock markets witnessed a rebound in early trade. The 30-share Sensex jumped 630.08 points to 77,261.73, while the Nifty climbed 203.6 points to 23,978.70.
Foreign Institutional Investors offloaded equities worth Rs 1,711.19 crore on Thursday, according to exchange data.
_vb_63.jpeg)